| Literature DB >> 28159773 |
Alexander Edwards1, Yifang Gao2,3, Raymond N Allan1,4, Darran Ball4, Hans de Graaf1,4,5, Tracy Coelho1,6, Vanessa Clifford7, Nigel Curtis7, Anthony Williams2,3,8,9, Saul N Faust1,4,10,11, Salah Mansour1, Ben Marshall1,10,12, Paul Elkington1,10,12, Marc Tebruegge1,7,10,11.
Abstract
The impact of immunosuppression on interferon-γ release assays and novel cytokine biomarkers of TB infection, mycobacteria-specific IL-2, IP-10 and TNF-α responses was investigated in an ex vivo model. Cytokine responses in standard QuantiFERON-TB Gold in-Tube (QFT-GIT) assays were compared with duplicate assays containing dexamethasone or infliximab. Dexamethasone converted QFT-GIT results from positive to negative in 30% of participants. Antigen-stimulated interferon-γ, IL-2 and TNF-α responses were markedly reduced, but IP-10 responses were preserved. Infliximab caused QFT-GIT result conversion in up to 30% of participants and substantial reductions in all cytokine responses. Therefore, corticosteroids and anti-TNF-α agents significantly impair interferon-γ release assay performance. IP-10 may be a more robust TB biomarker than interferon-γ in patients receiving corticosteroids. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.Entities:
Keywords: Tuberculosis
Mesh:
Substances:
Year: 2017 PMID: 28159773 DOI: 10.1136/thoraxjnl-2016-209397
Source DB: PubMed Journal: Thorax ISSN: 0040-6376 Impact factor: 9.139